{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"14","upperLimit":"71","value":"44"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"}],"units":"Participants"}],"description":"To evaluate the graft versus myeloma effect by monitoring rate of event-free survival (EFS)","dispersionType":"95% Confidence Interval","groups":[{"description":"A high-dose sequential chemotherapy approach with cyclophosphamide and etoposide followed by granulocyte colony stimulating factor (G-CSF) for collection of peripheral blood progenitor cells as well as for cytoreduction. Total Lymphoid irradiation and anti-thymocyte globulin (TLI/ATG).The preparatory regimens use BCNU and melphalan.","id":"OG000","title":"Autologous-Allogeneic Hematopoietic Stem Cell Transplant"}],"paramType":"NUMBER","populationDescription":"Includes all study participants","reportingStatus":"POSTED","timeFrame":"2 years after the last participant is enrolled","title":"Event-free Survival (EFS)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}